Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital

Quince Therapeutics (NASDAQ:QNCX)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They presently have a $12.00 target price on the stock.

Several other equities analysts also recently commented on the stock. RODMAN&RENSHAW raised shares of Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 29th. EF Hutton Acquisition Co. I raised shares of Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Rodman & Renshaw assumed coverage on shares of Quince Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $11.00 price objective for the company. Brookline Capital Management initiated coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, Maxim Group initiated coverage on shares of Quince Therapeutics in a report on Thursday, November 7th. They set a “buy” rating and a $6.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $9.50.

Quince Therapeutics Stock Performance

NASDAQ QNCX opened at $1.95 on Thursday. The firm has a market capitalization of $85.80 million, a price-to-earnings ratio of -1.57 and a beta of 0.74. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. The firm’s 50 day simple moving average is $1.80 and its 200 day simple moving average is $1.10. Quince Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.45.

Institutional Investors Weigh In On Quince Therapeutics

An institutional investor recently raised its position in Quince Therapeutics stock. Geode Capital Management LLC boosted its position in Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 339,125 shares of the company’s stock after purchasing an additional 66,170 shares during the period. Geode Capital Management LLC owned about 0.78% of Quince Therapeutics worth $263,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.